1. Introduction
nausea/vomiting, erosion, abdominal distention, gastritis, inflammation, gastritis-associated, pain, Inflammation, gastrointestinal (GI) motility, Gastritis
EROSION, GASTRITIS, INFLAMMATION, CHRONIC GASTRITIS, INFLAMMATION, GASTRITIS, DISEASES
Gastritis is defined as inflammation of the gastric mucosa which is confirmed by histological evaluation. It is a heterogeneous pathological condition and is one of the most common diseases to need medical consultation in Korea. Inflammation of the gastric mucosa results from an imbalance between mucosal defensive and aggressive factors such as gastric acidity, mucus-bicarbonate barrier, and gastric hormones (i.e., gastrin, pepsinogens I, II).The current treatment of gastritis is based mainly on controlling gastritis-associated symptoms, such as epigastric pain, nausea/vomiting, and abdominal distention, by using acid suppressive agents, gastrointestinal (GI) motility modulating agents, antacids or gastric mucoprotective agents.CKD-495, a product derived from In a previous phase II trial to assess the optimal dose and safety of CKD-495 for the treatment of gastritis (NCT03437785), CKD-495 75 mg demonstrated efficacy and safety for improving erosion in patients with acute or chronic gastritis (Chong Kun Dang Pharmaceutical Corp., data on file). The aim of this study was to compare the efficacy and safety of CKD-495 75 mg versus 